Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA

Emily P. Thi, Amy C H Lee, Joan B. Geisbert, Raul Ursic-Bedoya, Krystle N. Agans, Marjorie Robbins, Daniel J. Deer, Karla A. Fenton, Andrew S. Kondratowicz, Ian MacLachlan, Thomas Geisbert, Chad Mire

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Although significant progress has been made in developing therapeutics against Zaire ebolavirus, these therapies do not protect against other Ebola species such as Sudan ebolavirus (SUDV). Here, we describe an RNA interference therapeutic comprising siRNA targeting the SUDV VP35 gene encapsulated in lipid nanoparticle (LNP) technology with increased potency beyond formulations used in TKM-Ebola clinical trials. Twenty-five rhesus monkeys were challenged with a lethal dose of SUDV. Twenty animals received siRNA-LNP beginning at 1, 2, 3, 4 or 5days post-challenge. VP35-targeting siRNA-LNP treatment resulted in up to 100% survival, even when initiated when fever, viraemia and disease signs were evident. Treatment effectively controlled viral replication, mediating up to 4 log 10 reductions after dosing. Mirroring clinical findings, a correlation between high viral loads and fatal outcome was observed, emphasizing the importance of stratifying efficacy according to viral load. In summary, strong survival benefit and rapid control of SUDV replication by VP35-targeting LNP confirm its therapeutic potential in combatting this lethal disease.

Original languageEnglish (US)
Article number16142
JournalNature Microbiology
Volume1
DOIs
StatePublished - Aug 22 2016

Fingerprint

Ebolavirus
Sudan
Primates
Small Interfering RNA
Nanoparticles
Lipids
Infection
Viral Load
Democratic Republic of the Congo
Fatal Outcome
Viremia
Therapeutics
RNA Interference
Macaca mulatta
Fever
Clinical Trials
Technology
Genes

ASJC Scopus subject areas

  • Microbiology
  • Applied Microbiology and Biotechnology
  • Immunology
  • Microbiology (medical)
  • Cell Biology
  • Genetics

Cite this

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. / Thi, Emily P.; Lee, Amy C H; Geisbert, Joan B.; Ursic-Bedoya, Raul; Agans, Krystle N.; Robbins, Marjorie; Deer, Daniel J.; Fenton, Karla A.; Kondratowicz, Andrew S.; MacLachlan, Ian; Geisbert, Thomas; Mire, Chad.

In: Nature Microbiology, Vol. 1, 16142, 22.08.2016.

Research output: Contribution to journalArticle

Thi, EP, Lee, ACH, Geisbert, JB, Ursic-Bedoya, R, Agans, KN, Robbins, M, Deer, DJ, Fenton, KA, Kondratowicz, AS, MacLachlan, I, Geisbert, T & Mire, C 2016, 'Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA', Nature Microbiology, vol. 1, 16142. https://doi.org/10.1038/nmicrobiol.2016.142
Thi, Emily P. ; Lee, Amy C H ; Geisbert, Joan B. ; Ursic-Bedoya, Raul ; Agans, Krystle N. ; Robbins, Marjorie ; Deer, Daniel J. ; Fenton, Karla A. ; Kondratowicz, Andrew S. ; MacLachlan, Ian ; Geisbert, Thomas ; Mire, Chad. / Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. In: Nature Microbiology. 2016 ; Vol. 1.
@article{59282af12b8e4a06aeb7c72cc51911b6,
title = "Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA",
abstract = "Although significant progress has been made in developing therapeutics against Zaire ebolavirus, these therapies do not protect against other Ebola species such as Sudan ebolavirus (SUDV). Here, we describe an RNA interference therapeutic comprising siRNA targeting the SUDV VP35 gene encapsulated in lipid nanoparticle (LNP) technology with increased potency beyond formulations used in TKM-Ebola clinical trials. Twenty-five rhesus monkeys were challenged with a lethal dose of SUDV. Twenty animals received siRNA-LNP beginning at 1, 2, 3, 4 or 5days post-challenge. VP35-targeting siRNA-LNP treatment resulted in up to 100{\%} survival, even when initiated when fever, viraemia and disease signs were evident. Treatment effectively controlled viral replication, mediating up to 4 log 10 reductions after dosing. Mirroring clinical findings, a correlation between high viral loads and fatal outcome was observed, emphasizing the importance of stratifying efficacy according to viral load. In summary, strong survival benefit and rapid control of SUDV replication by VP35-targeting LNP confirm its therapeutic potential in combatting this lethal disease.",
author = "Thi, {Emily P.} and Lee, {Amy C H} and Geisbert, {Joan B.} and Raul Ursic-Bedoya and Agans, {Krystle N.} and Marjorie Robbins and Deer, {Daniel J.} and Fenton, {Karla A.} and Kondratowicz, {Andrew S.} and Ian MacLachlan and Thomas Geisbert and Chad Mire",
year = "2016",
month = "8",
day = "22",
doi = "10.1038/nmicrobiol.2016.142",
language = "English (US)",
volume = "1",
journal = "Nature Microbiology",
issn = "2058-5276",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA

AU - Thi, Emily P.

AU - Lee, Amy C H

AU - Geisbert, Joan B.

AU - Ursic-Bedoya, Raul

AU - Agans, Krystle N.

AU - Robbins, Marjorie

AU - Deer, Daniel J.

AU - Fenton, Karla A.

AU - Kondratowicz, Andrew S.

AU - MacLachlan, Ian

AU - Geisbert, Thomas

AU - Mire, Chad

PY - 2016/8/22

Y1 - 2016/8/22

N2 - Although significant progress has been made in developing therapeutics against Zaire ebolavirus, these therapies do not protect against other Ebola species such as Sudan ebolavirus (SUDV). Here, we describe an RNA interference therapeutic comprising siRNA targeting the SUDV VP35 gene encapsulated in lipid nanoparticle (LNP) technology with increased potency beyond formulations used in TKM-Ebola clinical trials. Twenty-five rhesus monkeys were challenged with a lethal dose of SUDV. Twenty animals received siRNA-LNP beginning at 1, 2, 3, 4 or 5days post-challenge. VP35-targeting siRNA-LNP treatment resulted in up to 100% survival, even when initiated when fever, viraemia and disease signs were evident. Treatment effectively controlled viral replication, mediating up to 4 log 10 reductions after dosing. Mirroring clinical findings, a correlation between high viral loads and fatal outcome was observed, emphasizing the importance of stratifying efficacy according to viral load. In summary, strong survival benefit and rapid control of SUDV replication by VP35-targeting LNP confirm its therapeutic potential in combatting this lethal disease.

AB - Although significant progress has been made in developing therapeutics against Zaire ebolavirus, these therapies do not protect against other Ebola species such as Sudan ebolavirus (SUDV). Here, we describe an RNA interference therapeutic comprising siRNA targeting the SUDV VP35 gene encapsulated in lipid nanoparticle (LNP) technology with increased potency beyond formulations used in TKM-Ebola clinical trials. Twenty-five rhesus monkeys were challenged with a lethal dose of SUDV. Twenty animals received siRNA-LNP beginning at 1, 2, 3, 4 or 5days post-challenge. VP35-targeting siRNA-LNP treatment resulted in up to 100% survival, even when initiated when fever, viraemia and disease signs were evident. Treatment effectively controlled viral replication, mediating up to 4 log 10 reductions after dosing. Mirroring clinical findings, a correlation between high viral loads and fatal outcome was observed, emphasizing the importance of stratifying efficacy according to viral load. In summary, strong survival benefit and rapid control of SUDV replication by VP35-targeting LNP confirm its therapeutic potential in combatting this lethal disease.

UR - http://www.scopus.com/inward/record.url?scp=84983509313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983509313&partnerID=8YFLogxK

U2 - 10.1038/nmicrobiol.2016.142

DO - 10.1038/nmicrobiol.2016.142

M3 - Article

C2 - 27670117

AN - SCOPUS:84983509313

VL - 1

JO - Nature Microbiology

JF - Nature Microbiology

SN - 2058-5276

M1 - 16142

ER -